Code | 9916C | ||||||||||
MA number | 59/0419/18-S | ||||||||||
Product Form: | cps dur 21x5 mg (blis.OPA/Al/PVC/Al) | ||||||||||
MA Status: | D - Marketing Authorisation valid for an unlimited period | ||||||||||
Type of procedure: | Decentralised | ||||||||||
MAH, country: | Glenmark Pharmaceuticals s.r.o., Czechia | ||||||||||
Therapeutic Class: | 59 - IMMUNOPRAEPARATA | ||||||||||
ATC: |
|
||||||||||
Shelf life: | 36 | ||||||||||
Container: | blister OPA/Al/PVC/Al | ||||||||||
Route of admin.: | Oral use |
Prescription Status: | Medicinal product subject to restricted medical prescription. |
Legal basis: | Article 10(1) generic application |
MA issued: | 19.12.2018 |
PIL: | PIL_Lenalidomid Glenmark_ 5mg_10mg_15mg_25mg_06.2023.pdf |
SPC: | SPC_Lenalidomid Glenmark_ 5mg_10mg_15mg_25mg_09.2024.pdf |
Safety feature | Yes |
Data update: | 06.10.2023 |